Cagrilintide (AM833) is a synthetic, lipidated 37-residue analogue of the pancreatic peptide amylin. Its N-terminus is acylated with icosanedioic acid (C20 diacid) through a γ-glutamyl spacer; the peptide carries a Cys2–Cys7 disulfide bond and a C-terminal proline amide, and its sequence was engineered to reduce the strong amyloid-fibril propensity of native amylin.

Cagrilintide has been characterized as a non-selective agonist of the amylin receptors AMY1R, AMY2R and AMY3R (heterodimers of the calcitonin receptor with receptor activity-modifying proteins, RAMPs) and of the calcitonin receptor (CTR) itself. Comparative pharmacology across receptor binding, activation and regulation endpoints reported a profile distinct from both amylin-selective and calcitonin-like agonists. Cryo-EM structures of Gs-coupled receptor complexes show an amylin-like 'bypass' binding mode with receptor-specific conformational dynamics.

It is used as a reference ligand in calcitonin-family GPCR pharmacology, RAMP–receptor signalling, cAMP and receptor-regulation assays, structural biology of class B GPCRs, and in vitro metabolism studies of lipidated amylin analogues. Lyophilized material is hygroscopic and should be stored desiccated and protected from light.

Research use only. This material is sold for in-vitro laboratory research and development purposes exclusively. It is not a drug, food, or dietary supplement, has not been evaluated by the FDA, and must not be used in humans or animals.